Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Staffing, Resource Gaps Makes Applying COVID Learnings To Other Disease Areas Challenging

Executive Summary

CBER Director Peter Marks hopes to run pilot programs that could convince Congress or industry to provide more funding that would enable FDA to offer pandemic-level communication with sponsors in 'normal' times.

You may also be interested in...



Peter Marks’ Fears May Come True: White House Wants More In-Person Work

The CBER director has worried that ‘someone’ might try to end the US FDA’s hybrid work policy. Now the push against it is bipartisan.

US FDA’s Marks Worries Someone May Stop Hybrid Work System

CBER Director Peter Marks said the FDA’s remote and in-person work system is functioning well and continues to help recruitment.

US FDA Still Not Scheduling In-Person Meetings Despite Sponsor Requests

Some sponsors appear to be growing antsy to meet with agency staff and advisory committees in-person, but CDER continues to schedule only virtual meetings.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS146999

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel